
WHI-P180
CAS No. 211555-08-7
WHI-P180( Janex 3 )
Catalog No. M13366 CAS No. 211555-08-7
WHI-P180 is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 51 | In Stock |
![]() ![]() |
5MG | 85 | In Stock |
![]() ![]() |
10MG | 124 | In Stock |
![]() ![]() |
25MG | 210 | In Stock |
![]() ![]() |
50MG | 311 | In Stock |
![]() ![]() |
100MG | 461 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameWHI-P180
-
NoteResearch use only, not for human use.
-
Brief DescriptionWHI-P180 is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.
-
DescriptionWHI-P180 is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.
-
In Vitro——
-
In VivoWHI-P180 is also an active inhibitor of IgE-mediated mast cell responses. The elimination half-life of WHI-P180 in CD-1 mice (BALB/c mice) following i.v., i.p., or p.o. administration is less than 10 min. Systemic clearance of WHI-P180 is 6742 mL/h/kg in CD-I mice and 8188 mL/h/kg in BALB/c mice. Notably, WHI-P180, when administered in two consecutive nontoxic i.p. bolus doses of 25 mg/kg, inhibits IgE/antigen-induced vascular hyperpermeability in a well-characterized murine model of passive cutaneous anaphylaxis.
-
SynonymsJanex 3
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK2| EGFR
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number211555-08-7
-
Formula Weight297.31
-
Molecular FormulaC16H15N3O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10 mM
-
SMILESOC1=CC=CC(NC2=C3C=C(OC)C(OC)=CC3=NC=N2)=C1
-
Chemical Name3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.An R, et al. Pharm Res. 2009 Feb;26(2):449-58.
molnova catalog



related products
-
SEL120-34A hydrochlo...
SEL120-34A is an ATP-competitive, selective, orally active CDK8 inhibitor that inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50 of 4.4 nM and 10.4 nM, respectively.
-
Tuberstemonine
Tuberstemonine exhibits relatively higher intestinal permeabilities.
-
MSC-2530818
MSC-2530818 (MSC 2530818, MSC2530818) is a potent, selective, and orally bioavailable CDK8 inhibitor with IC50 of 2.6 nM.